Addressing Sickle Cell Disease A Strategic Plan and Blueprint for Action (2020) / Chapter Skim
Currently Skimming:
Appendix L: Summary Table of Strategic Plan and Blueprint for Sickle Cell Disease Action
Appendix L: Summary Table of Strategic Plan and Blueprint for Sickle Cell Disease Action
Pages 481-488
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 481... ...
should appoint a team of experts from across HHS agencies to advance the strategic plan.
|
From page 482... ...
Recommendation 2-1 Review disability insurance qualifications Social Security Administration 1–2 years to ensure that the qualification criteria reflects the burden of the disease borne by SCD patients. Recommendation 2-2 Expand and enhance vocational States 2–3 years rehabilitation programs for individuals with SCD who need additional training in order to actively participate in the workforce.
|
From page 483... ...
, Sickle Cell Disease Association of America, Inc., Sickle Cell Adult Provider Network, and other key clinical disciplines and stakeholders engaged in SCD care, health systems, and parents and individuals living with SCD Recommendation 5-2 Develop and pilot reimbursement models Centers for Medicare & Medicaid 3–4 years for the delivery of coordinated SCD Services (CMS) , State Medicaid programs, health care and support services.
|
From page 484... ...
Recommendation 6-4 Disseminate information about NIH NIH, HRSA 1–2 yearsc and HRSA loan repayment programs and 3–5 yearsd designate SCD as a Population Health Professional Shortage Area under the National Health Service Corps program and create a Loan Repayment Program for health care professionals working with SCD populations.
|
From page 485... ...
, health professional associations, and state health departments Recommendation 8-1 Translate and disseminate emerging HHS, health professional associations, 2–3 years clinical research information to people health care providers, CBOs, and patient living with SCD and their families in order advocates to improve health literacy and empower them to engage in the care and treatment decision-making process. Recommendation 8-2 Engage the SCD population in designing HHS, state health departments, health 1–2 years educational and advocacy programs care providers, and CBOs and policies and in disseminating information on health and community services to individuals living with SCD and their caregivers.
|
From page 486... ...
Recommendation 7-2 Encourage and reimburse the practice NIH, FDA, pharmaceutical industry, and 1–2 yearse of shared decision making and the research community 3–5 yearsf development of decision aids for novel, high-risk, potentially highly effective therapies for individuals living with SCD. Recommendation 7-3 Establish an organized, systematic NIH, FDA, pharmaceutical industry, 2–3 years approach to encourage participation research community, and CBOs in clinical trials by including affected individuals in the design of trials, working with CBOs to disseminate information and recruit participants, and other targeted activities.
|
From page 487... ...
b Implement monitoring program to track performance on those indicators. c Disseminate information about existing loan repayment programs (e.g., for health disparities work)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.